Medical Center
Seoul, South Korea
NCT Number: NCT01093742
* Study Design
* Randomized, Double-blind, Placebo-controlled, escalating single-dose design. * Four ascending dose cohorts. * In each cohort, subjects will be randomized to receive a single dose of HM10560A or placebo (negative control). * Objectives
* The primary objective of the study is to assess the safety and tolerability of single escalating subcutaneous doses of HM10560A in healthy male subjects.
Looking for future studies?
Notify Me20 year–54 year
Male
Interventional
Phase 1
Seoul, South Korea
The secondary objectives of the study are as follows:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subcutaneously administrate at 0 hour on Day 1
Placebo
Time frame: 1, 2, 3, 5, 7, 11, 15, 22, 29 day after administration
Investigate Safety of HM10560A:
Hanmi Pharmaceutical Company Limited
Industry
A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of HM10560A After S.C. Administration in Healthy Male Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details